Defective DNA repair systems and the development of breast and prostate cancer (Review)

Kitagishi,Yasuko; Kobayashi,Mayumi; Matsuda,Satoru

doi:10.3892/ijo.2012.1696

Defective DNA repair systems and the development of breast and prostate cancer (Review)

Authors:
- Yasuko Kitagishi
- Mayumi Kobayashi
- Satoru Matsuda
View Affiliations

Affiliations: Department of Environmental Health Science, Nara Women's University, Nara 630-8506, Japan
Published online on: November 14, 2012 https://doi.org/10.3892/ijo.2012.1696
Pages: 29-34

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genetic defects in DNA repair and DNA damage response genes often lead to an increase in cancer incidence. The role of defects is also associated with the modulation of hormone signaling pathways. A number of studies have suggested a role for estrogen in the regulation of DNA repair activity. Furthermore, mutations or epigenetic silencing in DNA repair genes have been associated with the sensitivity of cancers to hormonal therapy. The molecular basis for the progression of cancers from hormone-dependent to hormone-independent remains a critical issue in the management of these types of cancer. In the present review, we aimed to summarize the function of DNA repair molecules from the viewpoint of carcinogenesis and hormone-related cell modulation, providing a comprehensive view of the molecular mechanisms by which hormones may exert their effects on the regulation of tumor progression.

View Figures

View References

1.	Folkerd EJ and Dowsett M: Influence of sex hormones on cancer progression. J Clin Oncol. 28:4038–4044. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Martin L, Coffey M, Lawler M, Hollywood D and Marignol L: DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. Cancer Lett. 291:142–149. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Xu Y and Price BD: Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle. 10:261–267. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, Pan Y, et al: DNA breaks and chromosome pulverization from errors in mitosis. Nature. 482:53–58. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Rodriguez GP, Romanova NV, Bao G, Rouf NC, Kow YW and Crouse GF: Mismatch repair-dependent mutagenesis in nondividing cells. Proc Natl Acad Sci USA. 109:6153–6158. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Vurusaner B, Poli G and Basaga H: Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med. 52:7–18. 2012. View Article : Google Scholar : PubMed/NCBI
7.	Hanel W and Moll UM: Links between mutant p53 and genomic instability. J Cell Biochem. 113:433–439. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Jones RM and Petermann E: Replication fork dynamics and the DNA damage response. Biochem J. 443:13–26. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Hennequin C, Quero L and Favaudon V: DNA repair and tumour radiosensitivity: focus on ATM gene. Bull Cancer. 98:239–246. 2011.PubMed/NCBI
11.	Molchadsky A, Rivlin N, Brosh R, Rotter V and Sarig R: p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis. 31:1501–1508. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Muller PA, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Essmann F and Schulze-Osthoff K: Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol. 165:328–344. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Karve TM, Li X and Saha T: BRCA1-mediated signaling pathways in ovarian carcinogenesis. Funct Integr Genomics. 12:63–79. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Berstein LM: Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol. 4:23–39. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Okumura N, Yoshida H, Kitagishi Y, Nishimura Y and Matsuda S: Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun. 413:395–399. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Mueck AO and Sitruk-Ware R: Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 76:531–539. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Bolton JL and Thatcher GR: Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol. 21:93–101. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Comstock CE and Knudsen KE: The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle. 6:1307–1313. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Lu S, Becker KA, Hagen MJ, Yan H, Roberts AL, Mathews LA, et al: Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology. 149:4809–4820. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, et al: FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 125:1735–1738. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Anaganti S, Fernández-Cuesta L, Langerød A, Hainaut P and Olivier M: p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Lett. 300:215–224. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Lee HJ, Chattopadhyay S, Yoon WH, Bahk JY, Kim TH, Kang HS, et al: Overexpression of hepatocyte nuclear factor-3alpha induces apoptosis through the upregulation and accumulation of cytoplasmic p53 in prostate cancer cells. Prostate. 70:353–361. 2010.PubMed/NCBI
24.	Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al: Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate. 70:1127–1133. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Welsh J: Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys. 523:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
26.	Ting HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, et al: A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res. 72:958–968. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Kelly GL and Strasser A: The essential role of evasion from cell death in cancer. Adv Cancer Res. 111:39–96. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Natarajan AT and Palitti F: DNA repair and chromosomal alterations. Mutat Res. 657:3–7. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Bhatti S, Kozlov S, Farooqi AA, Naqi A, Lavin M and Khanna KK: ATM protein kinase: the linchpin of cellular defenses to stress. Cell Mol Life Sci. 68:2977–3006. 2011. View Article : Google Scholar : PubMed/NCBI
30.	Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, Iseki S and Matsuda S: Against lung cancer cells: to be, or not to be, that is the problem. Lung Cancer Int. View Article : Google Scholar : 2012. View Article : Google Scholar
31.	Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR and Smith MA: Epigenetic mechanisms in gastric cancer. Epigenomics. 4:279–294. 2012. View Article : Google Scholar
32.	Martinez-Rivera M and Siddik ZH: Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol. 83:1049–1062. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Stegh AH: Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets. 16:67–83. 2012. View Article : Google Scholar : PubMed/NCBI
34.	Kim DH, Kundu JK and Surh YJ: Redox modulation of p53: mechanisms and functional significance. Mol Carcinog. 50:222–234. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Gartel AL: p21(WAF1/CIP1) and cancer: a shifting paradigm? Biofactors. 35:161–164. 2009. View Article : Google Scholar : PubMed/NCBI
36.	Ocker M and Schneider-Stock R: Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol. 39:1367–1374. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Osborne MP: Chemoprevention of breast cancer. Surg Clin North Am. 79:1207–1221. 1999. View Article : Google Scholar
38.	Roy R, Chun J and Powell SN: BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 12:68–78. 2011. View Article : Google Scholar : PubMed/NCBI
39.	Prado A, Andrades P and Parada F: Recent developments in the ability to predict and modify breast cancer risk. J Plast Reconstr Aesthet Surg. 63:1581–1587. 2010. View Article : Google Scholar : PubMed/NCBI
40.	Ohta T, Sato K and Wu W: The BRCA1 ubiquitin ligase and homologous recombination repair. FEBS Lett. 585:2836–2844. 2011. View Article : Google Scholar : PubMed/NCBI
41.	Leung CC and Glover JN: BRCT domains: easy as one, two, three. Cell Cycle. 10:2461–2470. 2011. View Article : Google Scholar : PubMed/NCBI
42.	Ouchi T: BRCA1 phosphorylation: biological consequences. Cancer Biol Ther. 5:470–475. 2006. View Article : Google Scholar : PubMed/NCBI
43.	Kotsopoulos J and Narod SA: Androgens and breast cancer. Steroids. 77:1–9. 2012. View Article : Google Scholar
44.	Dumitrescu RG: Epigenetic markers of early tumor development. Methods Mol Biol. 863:3–14. 2012. View Article : Google Scholar : PubMed/NCBI
45.	Centrella M and McCarthy TL: Estrogen receptor dependent gene expression by osteoblasts - direct, indirect, circumspect, and speculative effects. Steroids. 77:174–184. 2012. View Article : Google Scholar : PubMed/NCBI
46.	Wada-Hiraike O, Yano T, Nei T, Matsumoto Y, Nagasaka K, Takizawa S, et al: The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br J Cancer. 92:2286–2291. 2005. View Article : Google Scholar : PubMed/NCBI
47.	Murphy LC and Leygue E: The role of estrogen receptor-β in breast cancer. Semin Reprod Med. 30:5–13. 2012.
48.	Warner M and Gustafsson JA: The role of estrogen receptor beta (ERbeta) in malignant diseases - a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun. 396:63–66. 2012. View Article : Google Scholar : PubMed/NCBI
49.	Lamartiniere CA: Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia. 7:67–76. 2002. View Article : Google Scholar : PubMed/NCBI
50.	Shaik AP, Jamil K and Das P: CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. Urol J. 6:78–86. 2009.PubMed/NCBI
51.	Cancel-Tassin G and Cussenot O: Prostate cancer genetics. Minerva Urol Nefrol. 57:289–300. 2005.
52.	Agoulnik IU and Weigel NL: Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 99:362–372. 2006. View Article : Google Scholar : PubMed/NCBI
53.	Purohit A and Foster PA: Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol. 212:99–110. 2012. View Article : Google Scholar : PubMed/NCBI
54.	Banerjee S, Li Y, Wang Z and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett. 69:226–242. 2008. View Article : Google Scholar
55.	Park S and Choi J: Inhibition of beta-catenin/Tcf signaling by flavonoids. J Cell Biochem. 110:1376–1385. 2010. View Article : Google Scholar : PubMed/NCBI
56.	Power KA and Thompson LU: Can the combination of flaxseed and its lignans with soy and its isoflavones reduce the growth stimulatory effect of soy and its isoflavones on established breast cancer? Mol Nutr Food Res. 51:845–856. 2007. View Article : Google Scholar : PubMed/NCBI
57.	Sánchez Y, Amrán D, Fernández C, de Blas E and Aller P: Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK). Int J Cancer. 123:1205–1214. 2008.
58.	Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA and Stanford JL: Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev. 19:258–264. 2010. View Article : Google Scholar : PubMed/NCBI
59.	Lacroix-Triki M, Lambros MB, Geyer FC, Suarez PH, Reis-Filho JS and Weigelt B: Absence of microsatellite instability in mucinous carcinomas of the breast. Int J Clin Exp Pathol. 27:22–31. 2010.
60.	Norris AM, Woodruff RD, D’Agostino RB Jr, Clodfelter JE and Scarpinato KD: Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate. 67:214–225. 2007. View Article : Google Scholar : PubMed/NCBI
61.	Chen Y, Wang J, Fraig MM, Henderson K, Bissada NK, Watson DK, et al: Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol. 22:1033–1043. 2003.PubMed/NCBI
62.	Van Poppel H and Tombal B: Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res. 3:91–100. 2011.PubMed/NCBI
63.	Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, et al: Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 172:566–577. 2010. View Article : Google Scholar : PubMed/NCBI